



Ref: CTO 2014 019 [G]

Ovine & Cervine Placenta: Further Processing into Health Supplements

CTO direction to biosecurity inspectors for the direction of ovine and cervine placenta for further processing into health supplements.

Pursuant to section 27(1)(d)(iii) of the Biosecurity Act 1993 I, Marnie Thomas, Manager Animal Imports, Ministry for Primary Industries (under delegated authority), give the following direction for ovine and cervine placenta for further processing into health supplements to be given direction in accordance with the following measures, different from those in the applicable import health standard for the importation into New Zealand of specified animal products and biological (INEPROIC.ALL):

The ovine and cervine placenta must be imported into an approved transitional facility operating to MPI Standard MPI-STD-TFGEN (General Transitional Facilities for Uncleared Goods) Annex F (Animal Products).

At the transitional facility, the ovine and cervine placenta must be packaged into products that meet the eligibility criteria in clause 6.1 of INEPROIC.ALL:

- 6.1 Health supplements/Chinese and Oriental medicines containing animal products** from any country may be given clearance provided all the following requirements are met:
- i. The product shall be commercially manufactured and compounded into pills, tablets, capsules, liquids, syrups, oils or medicated plasters.
 - ii. The product shall be shelf-stable (i.e. not require refrigeration)
 - iii. The packaging or appearance of the packaging shall not indicate that the product is intended for animal use
 - iv. If the product is a liquid, it shall be contained within sealed packaging.

The reason for giving direction is that the biosecurity risks associated with this CTO direction have been assessed and are managed effectively.

This direction takes effect from the date of signing and continues in effect until amended or revoked.